Multiple sclerosis (MS) is a chronic, often disabling condition that affects the central nervous system, disrupting communication between the brain and body. It’s largely thought to occur when the ...
Justdial on MSN
Demystifying Multiple Sclerosis: From Symptoms to Treatment
Learn about multiple sclerosis, its symptoms, causes, and treatment options. Understand how early diagnosis helps in managing ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Tyruko, the first biosimilar to Tysabri injection, for the treatment of adults with ...
Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple sclerosis ...
–– Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) ...
(RTTNews) - Sandoz said that the U.S. Food and Drug Administration approved its biosimilar Tyruko (natalizumab-sztn), developed by Polpharma Biologics. Tyruko is approved to treat all indications ...
TG Therapeutics, Inc. announced new data presentations for BRIUMVI® (ublituximab-xiiy) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, highlighting its efficacy for ...
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback